Cardio Diagnostics Reports Q1 2026 Revenue Growth to $2,680, Net Loss Increases to $1.79M

Cardio Diagnostics Holdings, Inc. reported its financial results for the first quarter of 2026, revealing a revenue of $2,680, a significant increase from $940 in the same period last year. Despite this growth in revenue, the company recorded a net loss of $1,788,158, compared to a loss of $1,635,064 in the prior year, marking an increase in losses of $153,094. The rise in net loss was primarily attributed to higher general and administrative expenses, which increased due to annual franchise taxes and other operational costs.

The company's total operating expenses for the quarter were $1,787,517, up from $1,631,500 in the previous year. This increase was driven by higher costs in general and administrative functions, which accounted for $1,455,497, as well as increases in sales and marketing and research and development expenses. The company has been focusing on expanding its product offerings and enhancing its market presence, which has led to increased operational costs.

In terms of strategic developments, Cardio Diagnostics has been actively onboarding new providers and increasing the usage of its tests among existing clients. The company launched its second product, PrecisionCHD™, in March 2023, and has been working on expanding its reach into larger healthcare organizations and international markets, including a partnership in India. The establishment of a new high-complexity CLIA laboratory has also been completed, allowing the company to process patient samples internally, which is expected to reduce costs in the long run.

As of March 31, 2026, Cardio Diagnostics had cash and cash equivalents totaling $7,077,021, an increase from $5,110,630 at the end of 2025. The company generated $3,592,299 in cash from financing activities during the quarter, primarily from the sale of common stock. However, cash used in operating activities increased to $1,562,212, reflecting the ongoing investment in growth and operational capabilities. The company anticipates that it will continue to rely on external financing to support its operations and growth strategy, given the current revenue levels and ongoing expenses.

Looking ahead, Cardio Diagnostics aims to further develop its product line, enhance its sales and marketing efforts, and explore additional market opportunities both domestically and internationally. The company acknowledges the challenges of long sales cycles and the need for continued investment in research and development to support its growth objectives. Despite the current losses, management remains focused on achieving long-term profitability through strategic partnerships and product adoption.